Targeted therapy against triple-negative breast cancers, which lack expression of the estrogen, progesterone, and HER2 receptors, is not available and the overall response to cytotoxic chemotherapy is poor. One of the molecular hallmarks of triple-negative breast cancers is increased expression of genes that are transcriptionally activated by hypoxia-inducible factors (HIFs), which are implicated in many critical aspects of cancer progression including metabolism, angiogenesis, invasion, metastasis, and stem cell maintenance. Ganetespib is a second-generation inhibitor of heat shock protein 90 (HSP90), a molecular chaperone that is essential for the stability and function of multiple client proteins in cancer cells including HIF-1α. In this study, human MDA-MB-231 and MDA-MB-435 triple-negative breast cancer cells were injected into the mammary fat pad of immunodeficient mice that received weekly intravenous injections of ganetespib or vehicle following the development of palpable tumors. Ganetespib treatment markedly impaired primary tumor growth and vascularization, and eliminated local tissue invasion and distant metastasis to regional lymph nodes and lungs. Ganetespib treatment also significantly reduced the number of Aldefluor-positive cancer stem cells in the primary tumor. Primary tumors of ganetespibtreated mice had significantly reduced levels of HIF-1α (but not HIF-2α) protein and of HIF-1 target gene mRNAs encoding proteins that play key roles in angiogenesis, metabolism, invasion, and metastasis, thereby providing a molecular basis for observed effects of the drug on the growth and metastasis of triple-negative breast cancer.
Introduction
Metastasis is the final step in the progression of solid malignancies and the major cause of mortality in breast cancer patients. Intratumoral hypoxia is a characteristic property of advanced breast cancers that is associated with a significantly increased risk of metastasis [1] . Hypoxia-inducible factors (HIFs) activate the transcription of target genes that are involved in many aspects of breast cancer progression, such as angiogenesis, lymphangiogenesis, metabolic reprogramming, local tissue invasion, and metastasis by activating specific batteries of target genes [2, 3] . First, HIFs activate the transcription of genes encoding angiogenic growth factors, including vascular endothelial growth factor (VEGF) and stromal-derived factor 1 (SDF1), which play important roles in tumor vascularization [4, 5] . Second, HIFs regulate genes encoding proteins that mediate the switch from oxidative to glycolytic metabolism, including glucose transporter 1 (GLUT1), hexokinase 1 (HK1), HK2, and pyruvate dehydrogenase kinase 1 (PDK1) [3] . Third, HIFs activate transcription of genes encoding proteins, such as the collagen prolyl-4-hydroxylases (P4HA1 and P4HA2) and matrix metalloproteinase 9 (MMP9), which play key roles in local tissue invasion through remodeling of the extracellular matrix [6] [7] [8] . Fourth, HIFs control expression of genes encoding proteins, such as angiopoietin-like 4 (ANGPTL4), L1 cell adhesion molecule (L1CAM), and lysyl oxidase (LOX) that are required for metastasis [9] [10] [11] . Finally, HIF-1 has been implicated in the maintenance of tumorinitiating cells or cancer stem cells, although specific HIF target genes involved in this process have not been identified [12, 13] .
HIFs are heterodimeric transcription factors composed of an O 2 -regulated HIF-1α or HIF-2α subunit and a constitutively expressed HIF-1β subunit [14, 15] . Under normoxic conditions, proline hydroxylase domain protein 2 (PHD2) catalyzes hydroxylation of HIF-1α and HIF-2α, which is required for binding of the von Hippel-Lindau (VHL) tumor suppressor protein and the VHL-dependent recruitment of an Elongin C-containing ubiquitin ligase that targets HIF-1α and HIF-2α for ubiquitination and degradation by the 26S proteasome [15] . Also under normoxic conditions, asparagine hydroxylation by factor inhibiting HIF-1 (FIH-1) blocks binding of coactivators to the transactivation domain of HIF-1α and HIF-2α [15] . Under hypoxic conditions, PHD2 and FIH-1 activity are inhibited, leading to HIF-1α and HIF-2α protein stabilization, dimerization with HIF-1β, DNA binding, coactivator recruitment, and target gene transactivation. Heat shock protein 90 (HSP90) is a molecular chaperone that binds to HIF-1α and is required for its stability prior to dimerization with HIF-1β [16] [17] [18] [19] . Studies of the first-generation HSP90 inhibitors geldanamycin and 17-allylaminogeldanamycin revealed that displacement of HSP90 from HIF-1α allowed binding of the scaffold protein RACK1, which recruited Elongin C, leading to the ubiquitination and proteasomal degradation of HIF-1α [20] , regardless of the O 2 concentration or VHL status of the cell [17] .
Targeted therapies are available for breast cancers that express the estrogen/progesterone receptors (ER/PR), which are treated with tamoxifen or aromatase inhibitors, and those that express HER2, which are treated with trastuzumab or tyrosine kinase inhibitors. In contrast, targeted therapy is not available for triplenegative breast cancers that lack expression of the estrogen, progesterone, and HER2 receptors, account for~15 % of breast cancer cases, are treated with cytotoxic chemotherapy, and are associated with increased mortality compared to other breast cancer subtypes [21] . Several second-generation HSP90 inhibitors have been shown to inhibit the proliferation and survival of ER + /PR + , HER2 + , and triple-negative breast cancer cell lines in vitro and in subcutaneous tumor xenografts, which is associated with degradation of multiple HSP90 client proteins [22] [23] [24] .
Ganetespib (STA-9090) is a triazolone compound that is structurally unrelated to first-generation HSP90 inhibitors, with a superior antitumor activity and safety profile [25] . The X-ray crystal structure of ganetespib bound to the ATP pocket at the amino-terminus of HSP90 has been reported, providing a molecular basis for its inhibitory effect [25] . Ganetespib binding disrupts the interaction of HSP90 with the co-chaperone p23, which is required for efficient chaperone function [26] . In this study, we demonstrate for the first time that in addition to inhibiting primary tumor growth and vascularization, ganetespib blocks lymphatic and vascular metastasis of triple-negative breast cancer cells and impairs cancer stem cell maintenance in an orthotopic mouse model. We provide molecular evidence that decreased expression of HIF-1α and HIF-1 target genes plays an important role in the therapeutic effects of ganetespib.
Materials and methods

Cell culture
Human MDA-MB-231 and MDA-MB-435 breast cancer cells were obtained from the NCI PS-OC Network Bioresource Core Facility (National Institutes of Health) and cultured in Dulbecco's modified essential medium supplemented with 10 % fetal bovine serum and 1 % penicillin-streptomycin (Invitrogen) in a 5 % CO 2 /95 % air incubator at 37°C. The MDA-MB-231 and MDA-MB-435 cell lines were each authenticated by short tandem repeat profiling and tested negative for the presence of mycoplasma using a PCR-based assay. Cultured cells were pretreated with 100 nM ganetespib or vehicle for 30 min, exposed to 20 or 1 % O 2 for 6 h in the continued presence of drug, and then lysed for immunoblot assays.
Drug preparation
Ganetespib [3-(2,4-dihydroxy-5-isopropylphenyl)-4-(1-methyl-1H -1,2,4-triazol-5(4H )-one] was synthesized by Synta Pharmaceuticals Corp. and prepared as a stock solution in DMSO. For administration, ganetespib was formulated in vehicle consisting of 10 % DMSO, 18 % Cremophor RH 40, 3.6 % dextrose, and 68.4 % water [24] .
Orthotopic implantation Studies using 6-to 8-week-old female severe combined immunodeficiency (SCID) mice (NCI) were performed according to protocols approved by the Johns Hopkins University Animal Care and Use Committee in accordance with the NIH Guide for the Care and Use of Laboratory Animals. Cells were harvested from tissue culture plates by trypsinization, resuspended at 10 7 cells/ml in a 50:50 mixture of PBS/Matrigel (BD Biosciences), and 2×10 6 cells were injected into the mammary fat pad. Tumor length (L), width (W), and thickness (T) were measured (in millimeters) using calipers and tumor volume (V ) was calculated as V =0.52×L ×W ×T. After palpable tumors formed (7 days after tumor implantation), mice received a tail vein injection of ganetespib (150 mg/kg) or vehicle, which was repeated every 7 days. Tumor volume and body weight were monitored twice per week. Mice were euthanized 44 days after tumor implantation and 24 h after the last drug treatment. Following euthanasia, the left lung was inflated with low-melting-point agarose for formalin fixation, paraffin embedding, staining of tissue sections with hematoxylin and eosin (H&E), and immunohistochemistry. Portions of the right lung were used for the isolation of genomic DNA. Primary tumors were harvested for isolation of total RNA and protein lysate preparation. Blood was collected by heart puncture for RNA isolation. The axillary lymph node ipsilateral to the primary tumor was processed for immunohistochemistry [27] .
Extraction of genomic DNA Lung tissue was digested with proteinase K at 55°C overnight, and genomic DNA was extracted with phenol and chloroform, and precipitated with isopropanol. Two hundred nanograms of genomic DNA was used for quantitative realtime PCR (qPCR) using the following human HK2 genespecific primers to quantify lung metastatic burden: ccagttcattcacatcatcag and cttacacgaggtcacatagc. The result was normalized to the result obtained using primers that bind t o b o t h h u m a n a n d m o u s e 1 8 S r R N A g e n e s : cggcgacgacccattcgaac and gaatcgaaccctgattccccgtc.
Reverse transcription-qPCR Total RNA was extracted from using TRIzol (Invitrogen) and treated with DNase I (Ambion). One microgram of total RNA was used for first-strand cDNA synthesis using iScript cDNA Synthesis system (BioRad), and qPCR was performed using human-specific primers and SYBR Green qPCR Master Mix (Fermentas). For each primer pair, the annealing temperature was optimized by gradient PCR. The expression (E) of each target mRNA relative to human 18S rRNA in tumors from ganetespib-vs vehicle-treated mice was calculated based on the cycle threshold (Ct) as E =2
, in which ΔCt=Ct target −Ct 18S and Δ (ΔCt)=ΔCt ganetespib −ΔCt vehicle [28] . The nucleotide sequence of the primers is as follows: 18S rRNA, gaggatgaggtggaacgtgt and agaagtgacgcagccctcta; ALDH1A1, ctgctggcgacaatggagt and cgcaatgttttgatgcagcct; ALDH1A3, tgaatggcacgaatccaagag and cacgtcgggcttatctcct; ANGPTL4, tccaccgacctcccgttag and ctgttctgagccttgagttgtg; GLUT1, cgggccaagagtgtgctaaa and tgacgataccggagccaatg; HK2, ccagttcattcacatcatcag and cttacacgaggtcacatagc; L1CAM, gccacctgtcatcacggaac and gtccagcggaactgcacttc; LOX, gttccaagctggctactc and gggttgtcgtcagagtac; MMP9, gggacgcagacatcgtcatc and tcgtcatcgtcgaaatgggc; P4HA1, ccctgagactggaaaattgaccacagc and ggggttcatactgtcctccaactcca; P4HA2, gcctgcgctggaggaccttg and tgtgcctgggtccagcctgt; PDK1, ggattgcccatatcacgtcttt and tcccgtaaccctctagggaata; RPL13A, gaggcgagggtgatagag and acacacaagggtccaattc; SDF-1, actttagcttcgggtcaatgc and actttagcttcgggtcaatgc; and VEGF, cttgccttgctgctctac and tggcttgaagatgtactcg.
Immunoblot assays
Whole cell lysates were prepared in RIPA lysis buffer. Blots were probed with HIF-1α (1:1000, BD Transduction Laboratory), HIF-2α (1:500, Novus Biologicals) and HIF-1β (1:2000, Novus Biologicals) antibodies. HRP-conjugated anti-rabbit (Roche) and anti-mouse (Santa Cruz) secondary antibodies were used. Chemiluminescent signal was developed using ECL Plus (GE Healthcare).
Tumor hypoxia assay
Pimonidazole (Hypoxyprobe-1) was administered by intraperitoneal injection (60 mg/kg), and 60 min later the primary tumor was harvested, placed in 10 % formalin, and processed for immunohistochemistry using an anti-pimonidazole antibody (Natural Pharmacia International).
Immunohistochemistry
Primary tumors and ipsilateral axillary lymph nodes were fixed in 10 % formalin and paraffin embedded. Sections were dewaxed by xylene, hydrated with graded ethanols, followed by antigen retrieval using citrate buffer (pH 6.1). The LSAB+ System HRP kit (DAKO) was used with antibodies against vimentin (1:200, Santa Cruz), CD31 (1:20, Dianova, Germany), P4HA1 (1:100, Novus Biologicals), pimonidazole (1:100, Natural Pharmacia International), and Ki67 (1:100, Novus Biologicals). Sections were counterstained with Mayer's hematoxylin (Sigma). HIF-1α immunohistochemistry was performed as described [29] .
Digital image analysis
Immunohistochemical staining was quantified by Image J software (NIH). The acquired images in RGB color were separated into different color channels by a deconvolution method [30] . The Image J plug-in for color deconvolution has a built-in vector for separating hematoxylin and diaminobenzidine (DAB) staining. After color deconvolution, hematoxylin and DAB images were processed separately. By using six to eight random fields per tumor section stained with the antibody of interest, suitable threshold levels for hematoxylin and DAB were determined. These thresholds were used on both hematoxylin and DAB images and kept constant for analysis of the main image dataset. The extent of staining was calculated as the DAB-positive area divided by the hematoxylin-positive area. Six to eight fields, which encompassed the total surface area of each histological section, were analyzed. HIF-1α and Ki67 staining were calculated as the number of DAB-stained cells divided by the number of total cells per field. Vimentin, P4HA1 and pimonidazole staining were calculated as the DAB-positive area divided by the total tissue area per field. Blood vessel area was calculated as CD31-positive pixels divided by the total tissue area per field.
Aldefluor assay
To prepare primary tumor cells for flow cytometry analysis, tumor tissue was minced and digested with 1 mg/mL of type 1 collagenase (Sigma) at 37°C for 30 min. Digested tissue was filtered through a 70-μm cell strainer. The Aldefluor kit (Stem Cell Technologies) was used for fluorometric determination of aldehyde dehydrogenase activity; 1×10 6 cells obtained from freshly dissociated tumors were suspended in assay buffer c o n t a i n i n g t h e f l u o r e s c e n t s u b s t r a t e B O D I P Y aminoacetaldehyde (1 μmol/L) and incubated for 40 min at 37°C. As a negative control, for each tumor sample, an aliquot of cells was treated with the aldehyde dehydrogenase inhibitor diethylaminobenzaldehyde (DEAB; 50 mmol/L). Samples were subjected to flow cytometry analysis (FACScalibur, BD Biosciences).
Statistical Analysis
All data were expressed as mean±SEM. When data were not Gaussian, a logarithmic or square root transformation was applied. Differences between experimental groups were assessed using Student's test or two-way ANOVA. A p value<0.05 was considered statistically significant.
Results
Ganetespib treatment selectively inhibits accumulation of HIF-1α in hypoxic breast cancer cells
To investigate the effect of ganetespib on the accumulation of HIF-1α and HIF-2α in response to hypoxia, MDA-MB-231 [31] and MDA-MB-435 [32] triple-negative breast cancer cells were pretreated with 100 nM ganetespib or vehicle for 30 min and then exposed to 20 % or 1 % O 2 in the continued presence of drug for 6 h. Immunoblot assays revealed that hypoxia-induced accumulation of HIF-1α was markedly reduced, whereas HIF-2α levels were only modestly reduced (MDA-MB-231) or unaffected (MDA-MB-231) by Fig. 1 Ganetespib treatment inhibits accumulation of HIF-1α in MDA-MB-231 and MDA-MB-435 cells exposed to hypoxia. Cells were pretreated with ganetespib (100 nM) or vehicle for 30 min and exposed to 20 or 1 % O 2 for 6 h. Whole cell lysates were prepared and aliquots were subjected to immunoblot assay using antibodies against HIF-1α, HIF-2α, HIF-1β, or actin 6 MDA-MB-231 cells. When tumors became palpable, the mice were treated by tail vein injection of vehicle (Veh ) or ganetespib (Gan ; 150 mg/kg/week) starting on day 7 after orthotopic injection and weekly thereafter. a-c Tumor volume (a) and body weight (b) were determined twice weekly. On day 44, the mice were administered pimonidazole and, 1 h later, tumors were harvested and weighed (c). ***p <0.001 vs vehicle, twoway ANOVA or Student's t test (mean ± SEM; n = 9). d -f Immunohistochemistry was performed on tumor tissue sections from mice treated with Veh or Gan to analyze cell proliferation by Ki67 staining (d ), angiogenesis by CD31 staining (e ), and intratumoral hypoxia by pimonidazole staining (f). Representative photomicrographs are shown, with the bottom panel showing higher magnification of the insert from the top panel; scale bar =200 μm. g-i The stained sections were subjected to image analysis and quantification (mean±SEM); *p < 0.05, ***p <0.001 vs vehicle, Student's t test ganetespib treatment (Fig. 1) . Thus, ganetespib selectively inhibits accumulation of HIF-1α in human triple-negative breast cancer cells.
Ganetespib treatment inhibits primary tumor growth and vascularization after orthotopic implantation of MDA-MB-231 cells MDA-MB-231 human triple-negative breast cancer cells were implanted in the mammary fat pad of SCID mice. When tumors became palpable on day 7 after implantation, mice were randomized to treatment with ganetespib (150 mg/kg) or vehicle (N =9 mice in each group) by tail vein injection every 7 days over a six-week period. The growth of primary tumors in mice treated with ganetespib was significantly decreased compared with tumors in mice treated with vehicle (Fig. 2a) . There was no significant difference in body weight in ganetespib or vehicletreated mice between the start point and end point of the study on day 44 (Fig. 2b) . The final weight of tumors from ganetespib-treated mice was significantly decreased compared to tumors from vehicle-treated mice (Fig. 2c) . Consistent with the reduction in tumor growth, Ki67 staining (Fig. 2d) was significantly decreased in tumors from ganetespib-treated mice (Fig. 2g) . CD31 immunohistochemistry (Fig. 2e) revealed that blood vessel density was significantly decreased in tumors from ganetespib-treated mice (Fig. 2h) , which was associated with increased intratumoral hypoxia (Fig. 2i) as demonstrated by pimonidazole staining (Fig. 2f) . Thus, ganetespib treatment significantly reduced the growth and vascularization of primary tumors following orthotopic transplantation of human breast cancer cells. These results are consistent with those previously observed in mice bearing subcutaneous xenografts of non-small cell lung cancer cells [26] .
Ganetespib treatment inhibits HIF-1α expression, invasion, and metastasis
Immunohistochemical analysis of HIF-1α expression revealed strong nuclear staining at the tumor margin (Fig. 3a, b) and in central perinecrotic regions (Fig. 3c, d ) of tumor sections from vehicle-treated mice but not from ganetespib-treated mice. In addition to the lack of HIF-1α expression, the invasion of cancer cells into the surrounding stroma that was characteristic of the tumor margin in vehicle-treated mice was completely lost in ganetespib-treated mice, which showed a well-demarcated tumor-stroma border in all cases (Fig. 3a) . We previously demonstrated that HIF-1-dependent expression of P4HA1 was required for invasion and that MDA-MB-231 subclones in which P4HA1 expression was inhibited showed a strikingly similar loss of the invasive front [8] . Immunohistochemical detection of P4HA1 revealed a significant loss of expression in ganetespib-treated mice (Fig. 3e, f) .
To quantify the effect of ganetespib treatment on the expression of HIF subunits and HIF target gene products, we prepared tissue lysates and isolated total RNA from primary tumors. Immunoblot assays of tissue lysates revealed a dramatic decrease in HIF-1α protein levels in the primary tumors of ganetespib-treated mice, whereas levels of HIF-2α and HIF-1β were not affected by drug treatment (Fig. 4a, b) . Reverse transcription-qPCR (RT-qPCR) analyses (Fig. 4c) revealed a significant decrease in the levels of HIF-regulated mRNAs encoding proteins involved in glucose metabolism (GLUT1, HK2, PDK1), angiogenesis (VEGF), invasion (P4HA1), and metastasis (ANGPTL4, L1CAM, LOX). In contrast, expression of RPL13A mRNA, which is not regulated by HIF-1, was unaffected by drug treatment.
The spontaneous metastasis of breast cancer cells from the primary tumor was examined by H&E staining of lung sections (Fig. 5a ) to quantify the number of metastatic foci (Fig. 5b) and by a sensitive qPCR assay of lung genomic DNA using primers that were specific for the human HK2 gene to determine the total lung metastatic burden (Fig. 5c) . Remarkably, despite widespread metastases in vehicle-treated mice, no metastatic foci were observed and human HK2 DNA was not detected in lungs from ganetespib-treated mice. As a final measure of metastasis via blood vessels, we collected peripheral blood and screened for the presence of circulating tumor cells (CTCs) using a sensitive RT-qPCR assay that was specific for human 18S rRNA. CTCs were present in blood from vehicle-treated mice but absent in blood from ganetespib-treated mice (Fig. 5d) .
Lymphatic dissemination to the ipsilateral axillary lymph node was analyzed by immunohistochemistry with an antibody specific for human vimentin. Lymph nodes from vehicle-treated mice were markedly increased in size and displayed extensive staining for human vimentin, whereas no vimentin staining was observed in lymph nodes from ganetespib-treated mice (Fig. 5e, f) . Thus, ganetespib treatment completely eliminated metastasis of MDA-MB-231 breast cancer cells via blood vessels to the lungs and via lymphatics to the axillary lymph nodes.
Ganetespib inhibits primary tumor growth, vascular invasion, metastasis, and HIF target gene expression after orthotopic implantation of MDA-MB-435 cells
To confirm the results obtained after ganetespib treatment of mice orthotopically implanted with MDA-MB-231 cells, another human triple-negative breast cancer cell line, MDA-MD-435 (provenance of these cells is discussed in Ref. [32] ), was used for mammary fat pad injection. Once again, ganetespib dramatically inhibited primary tumor growth over 6 weeks (Fig. 6a) , with no effect on body weight (Fig. 6b) , leading to a marked reduction in final tumor weight (Fig. 6c) . Ganetespib treatment also abrogated the metastasis of MDA-MD-435 cells from the breast to the lungs, as determined by histology (Fig. 6d, e) and by qPCR (Fig. 6f) , and eliminated CTCs (Fig. 6g) . Analysis of total RNA isolated from primary tumors demonstrated a significant reduction in the expression of a panel of HIF target genes required for angiogenesis (SDF-1, VEGF), invasion (P4HA2, MMP9), and metastasis (ANGPTL4) but no change in the expression of RPL13A mRNA (Fig. 6h) .
Ganetespib treatment decreases the Aldefluor + cancer stem cell population in primary tumors A distinct subpopulation of cells within a breast tumor, designated cancer stem cells or tumor-initiating cells, is uniquely endowed with the capacity to regenerate a tumor and to form metastases, and these cancer stem cells can be identified by their expression of aldehyde dehydrogenase activity as measured by the Aldefluor assay [12, 33] . Following mammary fat pad implantation of MDA-MB-231 cells, the percentage of Aldefluor + cells decreased from 3.5 % in tumors from vehicletreated mice to 1 % in tumors from ganetespib-treated mice, a reduction of >70 % (Fig. 7a, b) . Levels of ALDH1A1 and ALDH1A3 mRNA, which encode the aldehyde dehydrogenases whose activity is measured by the Aldefluor assay [34, 35] , were significantly decreased in tumors from ganetespibtreated mice (Fig. 7c) . For MDA-MB-435 cells, Aldefluor + cells decreased from 2.5 % in primary tumors from vehicletreated mice to <1 % in tumors from ganetespib-treated mice (Fig. 7d, e) . Again, ALDH1A1 and ALDH1A3 mRNA levels were significantly decreased in tumors from ganetespibtreated mice (Fig. 7f) . To determine whether ALDH expression was directly HIF-regulated, cultured cells were exposed to 20 % or 1 % O 2 for 24 h. Neither ALDH1A1 nor ALDH1A3 mRNA expression was significantly induced by exposure of MDA-MB-231 (Fig. 7g) or MDA-MB-435 (Fig. 7h) 
cells to hypoxia.
Discussion
Previous studies have demonstrated that HSP90 inhibitors block the growth of established tumor xenografts after Fig. 4 Ganetespib treatment inhibits HIF-1α and HIF-1 target gene expression. a Tumors from mice treated with vehicle or ganetespib (n =5 each) were lysed and subjected to immunoblot assays with antibodies for HIF-1α, HIF-2α, HIF-1β, or actin. b Densitometry was performed and, for each sample, the density ratio of each protein to actin was determined. c Total RNA was isolated from tumors harvested from mice treated with vehicle (Veh) or ganetespib (Gan). Reverse transcription (RT) and quantitative real-time PCR (qPCR) were performed using primers specific for mRNA products of established HIF-1 target genes (GLUT1, HK2, PDK1, VEGF, P4HA1, ANGPTL4, L1CAM, and LOX) or a control gene that is not regulated by HIF-1 (RPL13A). mRNA levels were normalized to 18S rRNA levels in the same sample. For all bar graphs, *p <0.05, **p <0.01, ***p <0.001 vs vehicle, Student's t test (mean±SEM) subcutaneous injection of human breast cancer cells into immunodeficient mice [22] [23] [24] . In this study, we demonstrate for the first time that the second-generation HSP90 inhibitor ganetespib blocks the metastasis of human breast cancer cells when administered to mice intravenously on a once weekly schedule. Treatment was initiated after the primary tumor became palpable, 1 week after implantation of breast cancer cells into the mammary fat pad, when metastatic niche formation has already been initiated. Specifically, in the case of metastatic niche formation in the lungs of mice bearing MDA-MB-435 orthotopic tumors, collagen fiber formation in the lungs occurs within 8 days, bone marrow-derived cell recruitment to the lungs occurs within 16 days, and cancer cells are found with the metastatic niche within 24 days after implantation of cancer cells in the mammary fat pad [10] . Despite the rapid kinetics of metastasis in this model, weekly administration of ganetespib starting on day 7 was sufficient to completely eliminate lung metastasis.
Although HSP90 inhibitors have been shown previously to induce the degradation of many kinases (AKT, C-RAF, EGFR, ERK, GSK3, IGF-1Rβ, JNK, mTOR, SRC), transcription factors (C-JUN, MYC, STAT3, NF-κB p65, YAP) and other HSP90 client proteins that may contribute to breast cancer progression [22] [23] [24] , we demonstrate that treatment of Fig. 5 Ganetespib treatment inhibits vascular and lymphatic metastasis. Lungs, ipsilateral axillary lymph node, and peripheral blood were also collected on day 44 from tumor-bearing mice treated with vehicle (Veh) and ganetespib (Gan). a The left lung was fixed under inflation and sections were stained with hematoxylin and eosin (H&E) to identify metastatic foci. b The number of metastatic foci per field (6 random fields per section) was determined. c DNA was extracted from the right lung and analyzed by qPCR using primers specific for human HK2 gene sequences to quantify the total lung metastatic burden. d Total cellular RNA isolated from 0.5 ml of peripheral blood was analyzed by RT-qPCR using primers specific for human 18S rRNA as a measure of circulating tumor cells (CTCs). e The axillary lymph node ipsilateral to the mammary fat pad injection was harvested and analyzed by immunohistochemistry using an antibody specific for human vimentin. The lower panel is a high-power magnification of the insert in the upper panel; scale bar =200 μm. f Image analysis was performed to determine the vimentin positive area per field under ×40 magnification based on 6 random fields per section. For all bar graphs, ***p <0.001 vs vehicle, Student's t test (mean±SEM) Fig. 6 Ganetespib treatment inhibits tumor growth, metastasis, and HIF-1 target gene expression following orthotopic transplantation of MDA-MB-435 cells. SCID mice received a mammary fat pad injection of MDA-MB-435 cells followed by tail vein injection of vehicle (Veh) or ganetespib (Gan; 150 mg/kg/week) starting on day 7 after orthotopic injection and weekly thereafter. Tumor volume (a) and body weight (b) were determined twice weekly and final tumor weight was measured (c). Lung sections were stained with H&E (d) and the number of metastatic foci per lung section was determined (e ). Metastatic burden was determined by qPCR of lung genomic DNA using primers specific for the human HK2 gene (f). CTCs in peripheral blood were determined by RT-qPCR assay of total cellular RNA using primers specific for human 18S rRNA (g). Total RNA isolated from primary tumors was analyzed by RT-qPCR using primers specific for human VEGF, SDF-1, P4HA2, MMP9, ANGPTL4, and RPL13A mRNA normalized to the levels of 18S rRNA. For all bar graphs, **p <0.01, ***p <0.001 vs vehicle, twoway ANOVA or Student's t test (mean±SEM; n =6) tumor-bearing mice with ganetespib resulted in decreased HIF-1α levels within the tumor, which was associated with decreased expression of multiple mRNA products of known HIF-1 target genes that have been shown to play essential roles in breast cancer angiogenesis, metabolism, invasion, and metastasis (Fig. 8) . Ganetespib treatment inhibited the expression of SDF1 and VEGF mRNA, which was associated with decreased tumor vascularization. Decreased expression of multiple angiogenic factors was observed in colon cancer biopsies from patients treated with ganetespib [36] . Ganetespib treatment completely eliminated lung metastases and circulating tumor cells, which was associated with decreased expression of ANGPTL4, LOX, P4HA1, and P4HA2. Previous studies have demonstrated that HIF-1 directly activates transcription of the ANGPTL4, LOX , P4HA1, and P4HA2 genes in MDA-MB-231 cells and that knockdown of expression of any one of these genes inhibits lung metastasis [8, 9, 11] . Taken together, these results suggest that inhibition of HIF-1α expression contributed to the antimetastatic effect of ganetespib treatment.
In contrast to HIF-1α, HIF-2α protein levels were not reduced in the tumors of ganetespib-treated mice or in breast cancer cells cultured under hypoxic conditions. HIF-2α was reported to interact with HSP90 [19] , but overexpression of RACK1 in HEK293T cells only modestly decreased HIF-2α levels, whereas HIF-1α was efficiently degraded [20] , suggesting that HIF-1α may be more dependent upon HSP90 for stability. We have previously demonstrated that expression of short hairpin RNA targeting HIF-1α in MDA-MB-231 or MDA-MB-435 cells is sufficient to inhibit primary tumor growth and metastasis [10, 11] . Further studies are warranted to determine whether the preferential sensitivity of HIF-1α to ganetespib treatment is observed in other contexts.
We also show for the first time that ganetespib treatment reduced the Aldefluor + breast cancer stem cell population in vivo, which was associated with decreased expression of mRNAs encoding the aldehyde dehydrogenase isoforms ALDH1A1 and ALDH1A3. However, ALDH1A1 and ALDH1A3 mRNA expression was not induced when MDA-MB-231 and MDA-MB-435 cells were exposed to hypoxia for 24 h, indicating that HIF-1 does not directly regulate the expression of these genes. Thus, aldehyde dehydrogenase activity is a biomarker for the cancer stem cell phenotype, and the target genes regulated by HIF-1 that directly contribute to this phenotype remain to be identified. Inhibitory effects on other HSP90 client proteins may also contribute to the reduction in Aldefluor + cells in the primary tumors of ganetespib-treated mice. However, our results are consistent with previous reports demonstrating that exposure of cultured MDA-MB-231 and SUM159 triple-negative breast cancer cells to hypoxia for 2 to 6 days increased the Aldefluor + population by two-to four-fold in a HIF-1α-dependent and HIF-2α-independent manner [12] . The decreased Aldefluor + population in ganetespib-treated tumors stands in contrast to the increased Aldefluor + population that was observed in response to paclitaxel treatment of tumors derived from injection of MDA-MB-231 and other triple-negative breast cancer cell lines [37] .
Thus, inhibition of HIF-1 regulated genes provides a molecular basis for the effects of ganetespib treatment on Ganetespib also reduced the number of Aldefluor + cancer stem cells and decreased ALDH1A1 and ALDH1A3 mRNA levels, although the latter genes (purple rectangles) are not directly regulated by HIF-1 in breast cancer cells angiogenesis (SDF-1, VEGF), local tissue invasion and intravasation as measured by CTCs (P4HA1, P4HA2, MMP9), and lung metastasis, which requires CTCs to marginate (L1CAM) and extravasate (ANGPTL4) at sites of metastatic niche formation (LOX) and then, if they possess stem cell properties, to form a secondary tumor. The observed alterations in gene expression provide molecular evidence that inhibition of the HIF-regulated transcriptional program by ganetespib treatment contributed to the dramatic abrogation of lymphatic and vascular metastasis that was observed following orthotopic transplantation of two independent triplenegative breast cancer cell lines.
Our preclinical study was focused on triple-negative breast cancer because of the poor clinical outcome that is associated with cytotoxic chemotherapy, such as paclitaxel, which remains the standard of care in the absence of any available targeted therapy [21] . HIF-1 target gene expression represents a signature of basal/triple-negative breast cancers [38] and the results of the present study suggest that ganetespib may have therapeutic benefit in this patient population, either alone or in combination with cytotoxic chemotherapy. A phase II clinical trial (Clinicaltrials.gov identifier: NCT01677455) is currently underway to evaluate the effectiveness of intravenous administration of ganetespib (150 mg/m 2 twice weekly) to women with triple-negative (or HER2 + ) breast cancer. HIF-1α overexpression is associated with a significantly increased risk of metastasis and mortality in many other cancer types [39] and further studies are required to investigate whether ganetespib treatment may be beneficial in other clinical contexts in which targeted therapies are not available.
